Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

(2010) A. K. Hsu et al.   BLOOD

Dexamethasone Synergizes with Lenalidomide to Inhibit Multiple Myeloma Tumor Growth, But Reduces Lenalidomide-Induced Immunomodulation of T and NK Cell Function

(2010) A. K. Gandhi et al.   CURRENT CANCER DRUG TARGETS

Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysis

(2010) Rachid Baz et al.   LEUKEMIA & LYMPHOMA

Nodal Diffuse Large B-cell Lymphomas in Children and Adolescents: Immunohistochemical Expression Patterns and c-MYC Translocation in Relation to Clinical Outcome

(2009) Gabriela Gualco et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

(2009) L. Escoubet-Lozach et al.   CANCER RESEARCH

IRF4: Immunity. Malignancy! Therapy?

(2009) A. L. Shaffer et al.   CLINICAL CANCER RESEARCH

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

(2009) S Vincent Rajkumar et al.   LANCET ONCOLOGY

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

(2009) M A Dimopoulos et al.   LEUKEMIA

IRF-4 functions as a tumor suppressor in early B-cell development

(2008) J. Acquaviva et al.   BLOOD

Lenalidomide: a novel anticancer drug with multiple modalities

(2008) Christine Galustian et al.   EXPERT OPINION ON PHARMACOTHERAPY

IRF-4-Binding Protein Inhibits Interleukin-17 and Interleukin-21 Production by Controlling the Activity of IRF-4 Transcription Factor

(2008) Qinzhong Chen et al.   IMMUNITY

Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas

(2008) A L Feldman et al.   LEUKEMIA

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

(2008) Sonia Vallet et al.   LEUKEMIA & LYMPHOMA

A Role for Interferon Regulatory Factor 4 in Receptor Editing

(2008) S. Pathak et al.   MOLECULAR AND CELLULAR BIOLOGY

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE